Neovacs (ALNEV) | Stock Overview & Key Data
Neovacs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €2.00 on July 17, 2025
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Neovacs
ALNEV
|
190 Small-cap | 0.00% | 0.00% | -90.91% | -99.50% | 0.00% | -100.00% | -100.00% | -100.00% | -100.00% | -100.00% | -100.00% |
|
Abivax SA
ABVX
|
7.61B Large-cap | -36.61% | -28.82% | -25.31% | -26.24% | -38.04% | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
|
Nanobiotix
NANO
|
1.39B Large-cap | -12.69% | 13.65% | 14.38% | 69.14% | 58.63% | 827.52% | 612.13% | 134.60% | 81.06% | 449.03% | 449.03% |
|
Abionyx Pharma S.A
ABNX
|
128.36M Small-cap | -8.55% | -18.48% | -12.03% | -26.26% | -28.90% | 120.00% | 121.71% | 123.44% | -65.29% | -76.80% | -76.80% |
| 108.28M Small-cap | 0.00% | 23.20% | 42.59% | 42.59% | 42.59% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | 46.36% | |
|
Maat Pharma S.A.C.A
MAAT
|
99.87M Small-cap | 4.27% | -50.17% | -51.97% | -51.97% | -51.97% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% | -56.15% |
Ownership & Short Interest
Calculate Your Neovacs Investment Returns
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ALNEV's 52-week high and low?
- In the last 52 weeks, Neovacs reached a high of €4.20 (on N/A) and a low of €0.00 (on June 3, 2026).
- What is the market cap and P/E ratio for ALNEV?
- Curious about Neovacs's size and valuation? Its market capitalization stands at 190. When it comes to valuation, the P/E ratio (trailing twelve months) is 0.00, and the forward P/E (looking ahead) is 0.00.
- Does ALNEV pay dividends? If so, what's the yield?
- As for dividends, Neovacs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Neovacs's main competitors or similar companies to consider before investing?
When looking at Neovacs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX7.61B Healthcare Biotechnology 2,047.73% 517.65% Nanobiotix
NANO1.39B Healthcare Biotechnology 827.52% 612.13% Abionyx Pharma S.A
ABNX128.36M Healthcare Biotechnology 120.00% 121.71% Innate Pharma S.A
IPH108.28M Healthcare Biotechnology 46.36% 46.36% Maat Pharma S.A.C.A
MAAT99.87M Healthcare Biotechnology -56.15% -56.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Neovacs? (e.g., ROE, Debt/Equity)
- To get a sense of Neovacs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -23.23%, the Debt to Equity ratio from the most recent quarter is 0.90, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for ALNEV?
- Looking at Neovacs's growth, its revenue over the trailing twelve months (TTM) was €199K. Compared to the same quarter last year (YoY), quarterly revenue grew by -59.80%, and quarterly earnings saw a YoY growth of N/A.
- How much of ALNEV stock is held by insiders and institutions?
- Wondering who owns Neovacs stock? Company insiders (like executives and directors) hold about 0.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.